Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
0.7500 x 2 0.8100 x 51
Pre-market by (Cboe BZX)
0.8100 -0.1000 (-10.99%) 04/04/25 [NASDAQ]
0.7500 x 2 0.8100 x 51
Pre-market 0.8100 unch (unch) 07:06 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8100
Day High
0.9265
Open 0.9100
Previous Close 0.9100 0.9100
Volume 228,000 228,000
Avg Vol 237,815 237,815
Stochastic %K 13.84% 13.84%
Weighted Alpha -69.44 -69.44
5-Day Change -0.1500 (-15.62%) -0.1500 (-15.62%)
52-Week Range 0.8100 - 3.1200 0.8100 - 3.1200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,913
  • Shares Outstanding, K 82,609
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,840 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta 1.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.17
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings $-0.07 on 03/31/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 449.32% ( +60.50%)
  • Historical Volatility 70.10%
  • IV Percentile 92%
  • IV Rank 33.93%
  • IV High 1,206.81% on 01/15/25
  • IV Low 60.32% on 06/04/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 64
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 2,512
  • Open Int (30-Day) 5,029

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8100 unch
on 04/04/25
Period Open: 1.1300
1.2200 -33.61%
on 03/18/25
-0.3200 (-28.32%)
since 03/04/25
3-Month
0.8100 unch
on 04/04/25
Period Open: 1.4400
1.5100 -46.36%
on 02/06/25
-0.6300 (-43.75%)
since 01/03/25
52-Week
0.8100 unch
on 04/04/25
Period Open: 2.0400
3.1200 -74.04%
on 06/12/24
-1.2300 (-60.29%)
since 04/04/24

Most Recent Stories

More News
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...

CRDL.TO : 1.19 (-9.85%)
CRDL : 0.8100 (-10.99%)
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureToronto, Ontario--(Newsfile...

CRDL.TO : 1.19 (-9.85%)
CRDL : 0.8100 (-10.99%)
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL.TO : 1.19 (-9.85%)
CRDL : 0.8100 (-10.99%)
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...

CORT : 74.45 (-6.20%)
DYN : 8.28 (-12.10%)
CRDL : 0.8100 (-10.99%)
AMRX : 7.38 (-5.51%)
NKTR : 0.5519 (-8.09%)
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...

CORT : 74.45 (-6.20%)
DYN : 8.28 (-12.10%)
CRDL : 0.8100 (-10.99%)
AMRX : 7.38 (-5.51%)
NKTR : 0.5519 (-8.09%)
3 Penny Stocks Ready to Break Out in 2025

Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.

VUZI : 1.6900 (-5.59%)
CRDL : 0.8100 (-10.99%)
GOVX : 1.0200 (-7.27%)
Buy the Dip: 2 Cannabis ETFs Set to Benefit from Business-Friendly Policies

The recent appointment of Matt Gaetz as Attorney General has sparked controversy - and a surge in cannabis stocks. Two ETFs, AdvisorShares Pure Cannabis ETF (YOLO) and AdvisorShares Pure US Cannabis ETF...

YOLO : 1.5691 (-7.70%)
CURLF : 0.7713 (-9.26%)
SNDL : 1.3700 (-3.52%)
HITI : 1.8100 (-1.09%)
VFF : 0.5168 (-10.03%)
CRLBF : 0.5925 (-4.44%)
CRDL : 0.8100 (-10.99%)
TCNNF : 3.2300 (-9.01%)
VRNOF : 0.5400 (-8.07%)
GTBIF : 5.0200 (-5.82%)
MSOS : 2.16 (-7.69%)
Stocks in play: Cardiol Therapeutics Inc.

Reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact ...

CRDL : 0.8100 (-10.99%)
Five Top Heart Health Stocks to Buy Heading into 2025

Heart health statistics are startling. Not only is heart disease the leading cause of death in the United States, it also claims the life of one person every 33 seconds. Plus, the estimated global annual...

ABT : 124.44 (-5.46%)
BSX : 89.70 (-8.93%)
CRDL : 0.8100 (-10.99%)
GILD : 107.25 (-4.57%)
MDT : 82.88 (-5.70%)
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing...

CRDL.TO : 1.19 (-9.85%)
CRDL : 0.8100 (-10.99%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.0042
2nd Resistance Point 0.9653
1st Resistance Point 0.8877
Last Price 0.8100
1st Support Level 0.7712
2nd Support Level 0.7323
3rd Support Level 0.6547

See More

52-Week High 3.1200
Fibonacci 61.8% 2.2376
Fibonacci 50% 1.9650
Fibonacci 38.2% 1.6924
Last Price 0.8100
52-Week Low 0.8100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades